Ischemic preconditioning triggers nuclear translocation of thioredoxin and its interaction with Ref-1 potentiating a survival signal through the PI-3-kinase-Akt pathway.

Thioredoxin (Trx-1), a key mediator of cellular redox homeostasis and cell survival, is implicated in redox signaling in the ischemic myocardium. To investigate further its mechanism of action, Trx expression in rat heart was suppressed by direct injection of small hairpin RNA against Trx-1 (shRNA-Trx-1). Forty-eight hours after treatment, hearts were excised for isolated working-heart preparation. A group of hearts was preconditioned (PC) by subjecting them to four cyclic episodes of 5-min ischemia, each followed by 10 min of reperfusion. All the hearts, PC or non-PC, were subjected to 30-min ischemia followed by 2 h of reperfusion. As expected, the PC hearts exhibited improved ventricular function, reduced infarct size, and cardiomyocyte apoptosis. Also in PC hearts, an increase was noted in Trx-1 and other cardioprotective and redox-regulated proteins like Ref-1, phospho-Akt, and NF-kappaB DNA-binding activity. PC also caused nuclear translocation of Trx-1 and Ref-1 followed by their association. However, in hearts treated with shRNA-Trx 1, the cardioprotective effects of PC were abolished along with a concomitant decrease in nuclear localized Trx-1 and Ref-1, along with a decrease in phospho-Akt and NF-kappaB. These results demonstrate that PC triggers translocation of Trx-1 into the nucleus, where it becomes associated with Ref-1 and performs redox signaling through the activation of NF-kappaB and an increase in prosurvival signal inducer phospho-Akt.

[1]  K. Schulze-Osthoff,et al.  Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Holmgren,et al.  [21] Thioredoxin and thioredoxin reductase , 1995 .

[3]  T. Okamoto,et al.  Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. , 1993, The Journal of biological chemistry.

[4]  H. Masutani,et al.  Transactivation of an inducible anti-oxidative stress protein, human thioredoxin by HTLV-I Tax. , 1996, Immunology letters.

[5]  D. Das.  Thioredoxin regulation of ischemic preconditioning. , 2004, Antioxidants & redox signaling.

[6]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[7]  S. Osborne,et al.  Thioredoxin-mediated redox control of the transcription factor Sp1 and regulation of the thioredoxin gene promoter. , 2003, Gene.

[8]  R. Kitsis,et al.  Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. , 2000, Circulation.

[9]  C. Kawai,et al.  Upregulation of redox-regulating protein, thioredoxin, in endomyocardial biopsy samples of patients with myocarditis and cardiomyopathies , 2003, Molecular and Cellular Biochemistry.

[10]  J. Yodoi,et al.  A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (Trx) gene. , 1996, Nucleic acids research.

[11]  M. Djavaheri-Mergny,et al.  NF‐κB activation prevents apoptotic oxidative stress via an increase of both thioredoxin and MnSOD levels in TNFα‐treated Ewing sarcoma cells , 2004 .

[12]  B. Price,et al.  An essential role of NFκB in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia , 1998, FEBS letters.

[13]  J. Yodoi,et al.  Cutaneous arteriolar thioredoxin expression in patients with heart failure. , 2003, Circulation journal : official journal of the Japanese Circulation Society.

[14]  A. Holmgren,et al.  Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery. , 1998, Free radical biology & medicine.

[15]  J. Yodoi,et al.  Protective effect of adult T-cell leukemia-derived factor on retinal ischemia-reperfusion injury in the rat. , 1998, Investigative ophthalmology & visual science.

[16]  P. Hainaut,et al.  Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity , 2005, Oncogene.

[17]  H. Wada,et al.  Protection against reperfusion-induced arrhythmias by human thioredoxin. , 1996, Journal of cardiovascular pharmacology.

[18]  G. Powis,et al.  Nuclear Factor κB Transactivation Is Increased But Is Not Involved in the Proliferative Effects of Thioredoxin Overexpression in MCF-7 Breast Cancer Cells , 1999 .

[19]  W. Chen,et al.  Ischemic Preconditioning Activates Phosphatidylinositol-3-Kinase Upstream of Protein Kinase C , 2000, Circulation research.

[20]  J. Yodoi,et al.  Human thioredoxin attenuates hypoxia‐reoxygenation injury of murine endothelial cells in a thiol‐free condition , 2000, Journal of cellular physiology.

[21]  Y. Makino,et al.  Direct Association with Thioredoxin Allows Redox Regulation of Glucocorticoid Receptor Function* , 1999, The Journal of Biological Chemistry.

[22]  N. Maulik,et al.  Differential regulation of Bcl‐2, AP‐1 and NF‐κB on cardiomyocyte apoptosis during myocardial ischemic stress adaptation , 1999, FEBS letters.

[23]  D. Das,et al.  Transgene overexpression of αB crystallin confers simultaneous protection against cardiomyocyte apoptosis and necrosis during myocardial ischemia and reperfusion , 2001 .

[24]  K. Mori,et al.  AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Kaghad,et al.  Genomic cloning of human thioredoxin-encoding gene: mapping of the transcription start point and analysis of the promoter. , 1994, Gene.